Literature DB >> 16541312

Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.

Marijke Wasielewski1, Fons Elstrodt, Jan G M Klijn, Els M J J Berns, Mieke Schutte.   

Abstract

The p53 tumor suppressor gene is frequently mutated in breast cancer. Here, we used direct sequencing to screen the complete coding sequence of the p53 gene from 41 human breast cancer cell lines. We identified 32 cell lines (78%) with a p53 gene alteration that predicted a change in the encoded protein. Thirty-one of these mutations were accompanied by loss of the other p53 allele. All mutations but one were unique and 27 mutations had previously been identified in uncultured human cancers. Ten mutations were predicted to encode a truncated p53 protein and 22 missense mutations were identified. p53 transcript expression was analyzed by semi-quantitative RT-PCR and p53 protein expression was determined by Western blotting. Our analyses revealed three p53 expression patterns: wild-type p53 cell lines had normal transcript levels and low or no detectable protein expression; cell lines with a p53 truncating mutation had low transcript levels and low or no detectable protein expression; and cell lines with a p53 missense mutation had highly variable transcript and protein expression levels. As a whole, our data represent a p53 mutation profile in breast cancer cell lines, providing a model for structural, functional and pharmacological studies on p53 in human cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16541312     DOI: 10.1007/s10549-006-9186-z

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  43 in total

1.  Deregulation of Internal Ribosome Entry Site-Mediated p53 Translation in Cancer Cells with Defective p53 Response to DNA Damage.

Authors:  Marie-Jo Halaby; Benjamin R E Harris; W Keith Miskimins; Margot P Cleary; Da-Qing Yang
Journal:  Mol Cell Biol       Date:  2015-09-21       Impact factor: 4.272

2.  The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells.

Authors:  Shaneabbas Raza; Joyce E Ohm; Archana Dhasarathy; Jared Schommer; Conor Roche; Kimberly D P Hammer; Othman Ghribi
Journal:  Mol Cell Biochem       Date:  2015-09-08       Impact factor: 3.396

3.  Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents.

Authors:  Xiaokai Li; Sharan R Srinivasan; Jamie Connarn; Atta Ahmad; Zapporah T Young; Adam M Kabza; Erik R P Zuiderweg; Duxin Sun; Jason E Gestwicki
Journal:  ACS Med Chem Lett       Date:  2013-11-14       Impact factor: 4.345

4.  Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.

Authors:  Hillary Stires; Mary M Heckler; Xiaoyong Fu; Zhao Li; Catherine S Grasso; Michael J Quist; Joseph A Lewis; Uwe Klimach; Alan Zwart; Akanksha Mahajan; Balázs Győrffy; Luciane R Cavalli; Rebecca B Riggins
Journal:  Mol Cell Endocrinol       Date:  2017-09-19       Impact factor: 4.102

5.  Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.

Authors:  Jennifer J Jordan; Alberto Inga; Kathleen Conway; Sharon Edmiston; Lisa A Carey; Lin Wu; Michael A Resnick
Journal:  Mol Cancer Res       Date:  2010-04-20       Impact factor: 5.852

6.  Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer.

Authors:  Mari Gasparyan; Miao-Chia Lo; Hui Jiang; Chang-Ching Lin; Duxin Sun
Journal:  J Biol Chem       Date:  2020-05-28       Impact factor: 5.157

7.  Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer.

Authors:  D Maglic; S Zhu; E A Fry; P Taneja; F Kai; R D Kendig; T Sugiyama; L D Miller; M C Willingham; K Inoue
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

8.  Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells.

Authors:  Lu Chen; Julie Ann Mayer; Tibor I Krisko; Corey W Speers; Tao Wang; Susan G Hilsenbeck; Powel H Brown
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

Review 9.  Scaffolding actions of membrane-associated progesterone receptors.

Authors:  Christy R Hagan; Emily J Faivre; Carol A Lange
Journal:  Steroids       Date:  2008-12-24       Impact factor: 2.668

10.  Androgen receptor as a targeted therapy for breast cancer.

Authors:  Joseph P Garay; Ben H Park
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.